Sage Therapeutics (SAGE) Scheduled to Post Quarterly Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGEGet Rating) will be posting its quarterly earnings results before the market opens on Tuesday, May 3rd. Analysts expect Sage Therapeutics to post earnings of ($2.06) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGEGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($2.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.16) by $0.04. Sage Therapeutics had a negative return on equity of 24.43% and a negative net margin of 7,258.91%. The firm had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $1.77 million. During the same quarter last year, the firm earned ($2.47) EPS. The business’s quarterly revenue was down 99.9% on a year-over-year basis. On average, analysts expect Sage Therapeutics to post $-8 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Shares of SAGE opened at $33.22 on Tuesday. The stock has a 50-day moving average of $34.40 and a two-hundred day moving average of $39.06. Sage Therapeutics has a one year low of $30.48 and a one year high of $80.87. The stock has a market cap of $1.96 billion, a P/E ratio of -4.26 and a beta of 1.65.

Several institutional investors have recently made changes to their positions in the stock. Morgan Stanley increased its stake in shares of Sage Therapeutics by 133.7% in the 2nd quarter. Morgan Stanley now owns 577,716 shares of the biopharmaceutical company’s stock valued at $32,820,000 after purchasing an additional 330,541 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Sage Therapeutics by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 259,034 shares of the biopharmaceutical company’s stock valued at $11,020,000 after purchasing an additional 3,101 shares in the last quarter. Nuveen Asset Management LLC increased its stake in shares of Sage Therapeutics by 5.3% in the 4th quarter. Nuveen Asset Management LLC now owns 247,614 shares of the biopharmaceutical company’s stock valued at $10,534,000 after purchasing an additional 12,563 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Sage Therapeutics by 41.6% in the 4th quarter. Alliancebernstein L.P. now owns 128,055 shares of the biopharmaceutical company’s stock valued at $5,447,000 after purchasing an additional 37,609 shares in the last quarter. Finally, Credit Suisse AG increased its stake in Sage Therapeutics by 11.0% during the 4th quarter. Credit Suisse AG now owns 80,947 shares of the biopharmaceutical company’s stock worth $3,443,000 after buying an additional 8,005 shares in the last quarter. Hedge funds and other institutional investors own 82.64% of the company’s stock.

A number of brokerages have commented on SAGE. Canaccord Genuity Group lowered their price target on Sage Therapeutics from $95.00 to $64.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Needham & Company LLC lifted their price target on Sage Therapeutics from $79.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, January 6th. Truist Financial lowered their price target on Sage Therapeutics from $60.00 to $40.00 and set a “hold” rating for the company in a research report on Wednesday, March 9th. Mizuho lowered their price target on Sage Therapeutics from $44.00 to $41.00 and set a “neutral” rating for the company in a research report on Thursday, March 3rd. Finally, Morgan Stanley lowered their price target on Sage Therapeutics from $61.00 to $57.00 and set an “equal weight” rating for the company in a research report on Thursday, March 10th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $63.16.

About Sage Therapeutics (Get Rating)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.

See Also

Earnings History for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.